Tyler Armstrong, 9, Summits Mt. Aconcagua and Raises Awareness to Benefit CureDuchenne
Newport Beach, Calif.
NEWPORT BEACH, Calif., December 31, 2013 – Nine-year-old Tyler Armstrong of Yorba Linda, Calif., became the youngest person to summit Mt. Aconcagua in Argentina when he reached the top of the 22,837 ft. mountain on Christmas Eve. Tyler climbed Mt. Aconcagua to benefit CureDuchenne, a nonprofit that raises awareness and funds research to find a cure for Duchenne muscular dystrophy. Tyler arrives home from his adventure today.
“It was amazing to be on top of Mt. Aconcagua above the clouds with my dad,” said Tyler. “Some boys my age with Duchenne can’t walk. I want the world to know about Duchenne so they can find a cure. I want Duchenne boys to have a chance to live.”
Duchenne is a progressive muscle-wasting disease that impacts 1 in 3,500 boys. Boys are usually diagnosed by 5, in a wheelchair by 12 and most don’t survive their mid-20s. Tyler continues to fundraise for CureDuchenne to support the most promising research projects aimed at treating and curing Duchenne.
“We are so proud of Tyler for reaching the summit of Mt. Aconcagua on behalf of CureDuchenne,” said Debra Miller, founder and CEO of CureDuchenne. “Tyler is a brave and compassionate boy like the boys and young men who live with Duchenne every day. We are grateful that Tyler has been able to reach new heights and help us raise awareness and money to find a cure for Duchenne.”
Visit www.cureduchenne.org/goto/Tyler to donate to Tyler’s climb and raise money to fund Duchenne research. For more information on CureDuchenne, go to www.cureduchenne.org or call 949-872-2552. Follow us on Facebook, Twitter and YouTube.
CureDuchenne is a national nonprofit organization located in Newport Beach, Calif., dedicated to finding a cure for Duchenne, the most common and most lethal form of muscular dystrophy. As the leading genetic killer of young boys, Duchenne affects more than 300,000 boys worldwide.
CureDuchenne has garnered international attention for its efforts to raise funds and awareness for Duchenne through venture philanthropy. With the help of CureDuchenne’s distinguished international panel of Scientific Advisors, funds raised by CureDuchenne support the most promising research aimed at treating and curing Duchenne. To date, seven CureDuchenne research projects have made their way into human clinical trials – a unique accomplishment as few health-related nonprofits have been successful in being a catalyst for human clinical trials.